Content: a call for tenders for the community program called EU4Health is open until 5 September within the crisis preparation chapter of the 2024 work programme. 
The call co-finances actions that will be managed by the European Authority for Health Emergency Preparedness and Response (HERA).  In particular, 102 million euros have been 
allocated for the creation of a European hub for the development of vaccines (ref. EU4H-2024-PJ-01-1 - CP-g-24-10). The aim is to create a European hub for the development of 
vaccines relevant to public health, combining excellence in vaccine development with clinical trials and scaled-up manufacturing activities. Consortia of vaccine developers 
spanning development experience, including organisations, publicly funded SMEs and industry, are eligible to participate.
The hub should establish links with the future European Partnership on Pandemic Preparedness funded by the Horizon Europe program and with private producers, including through 
specific production agreements.  While twenty million euros are allocated to projects for the creation of next generation personal protective respiratory devices (ref. 
EU4H-2024-PJ-01-2 -CP-g-24-11). Co-financing applications can be submitted both for the development of completely new technologies and for the advancement of reformulated 
projects and also request contributions for new applications of materials and for innovative interventions on existing technologies. Detailed project plans, prototyping phases,
 validation interventions and CE marking for innovative, economical and sustainable new generation respirators can be co-financed. Respirators must offer higher levels of 
protection than FFP2 respirators and be universally fit, allowing for comfortable use for longer hours.
The different solutions can be aimed at different groups of citizens such as, for example, doctors, critical workers, the public, etc.). Each proposal must include a 
deployment and market preparation plan that ensures a market for the product during preparation periods, for example through storage or active use. Each plan must generate
 sufficient demand to justify a planned phased production start-up. The call then provides for an amount of 17 million euros dedicated to supporting innovative technologies 
and innovative production processes in the European Union for the production of medicines (ref. EU4H-2024-PJ-01-3 CP-g-24- 12). Activities aimed at developing support or 
innovation aimed at the production of active pharmaceutical ingredients (APIs), their intermediates and/or excipients, in particular by developing new production processes
 and technologies, will therefore be able to obtain a community contribution.
References:

Hadea - Agenzia esecutiva europea per la salute e il digitale – https://hadea.ec.europa.eu/index_en - https://ec.europa.eu/info/funding-tenders/opportunities/calls-for-proposals